Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov–Smirnov Algorithm

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–361. doi:10.1038/nature0166112748655
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136. doi:10.1016/j.autrev.2004.09.00215823498
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. doi:10.1136/annrheumdis-2015-20752425969430
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi:10.1002/art.39480
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi:10.1136/annrheumdis-2013-20457324161836
   PubMed Web of Science ®Google Scholar
• Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013;93(4):335–341. doi:10.1038/clpt.2013.123443757
   PubMed Web of Science ®Google Scholar
• Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science. 2009;324(5933):1394–1395. doi:10.1126/science.116992019520944
   PubMed Web of Science ®Google Scholar
• Cheng F, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol. 2012;8(5):e1002503. doi:10.1371/journal.pcbi.100250322589709
   PubMed Web of Science ®Google Scholar
• Luo H, Chen J, Shi L, et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011;39(Web Server issue):W492–W498. doi:10.1093/nar/gkr29921558322
   PubMed Web of Science ®Google Scholar
• Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. PLoS One. 2011;6(12):e28025. doi:10.1371/journal.pone.002802522205936
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935. doi:10.1126/science.113293917008526
   PubMed Web of Science ®Google Scholar
• Li J, Zhu X, Chen JY. Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput Biol. 2009;5(7):e1000450. doi:10.1371/journal.pcbi.100045019649302
   PubMed Web of Science ®Google Scholar
• Dopazo J. Genomics and transcriptomics in drug discovery. Drug Discov Today. 2014;19(2):126–132. doi:10.1016/j.drudis.2013.06.00323773860
   PubMed Web of Science ®Google Scholar
• Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–381. doi:10.1038/nature1287324390342
   PubMed Web of Science ®Google Scholar
• Kurko J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. Genetics of rheumatoid arthritis – a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):170–179. doi:10.1007/s12016-012-8346-723288628
   PubMed Web of Science ®Google Scholar
• Mathews RJ, Robinson JI, Battellino M, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis. 2014;73(6):1202–1210. doi:10.1136/annrheumdis-2013-20327623687262
   PubMed Web of Science ®Google Scholar
• Teixeira VH, Olaso R, Martin-Magniette ML, et al. Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients. PLoS One. 2009;4(8):e6803. doi:10.1371/journal.pone.000680319710928
   PubMed Web of Science ®Google Scholar
• Walsh AM, Whitaker JW, Huang CC, et al. Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations. Genome Biol. 2016;17:79. doi:10.1186/s13059-016-0948-627140173
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology. Nature. 1999;402(6761 Suppl):C47–C52. doi:10.1038/3501154010591225
   PubMed Web of Science ®Google Scholar
• Glazko GV, Emmert-Streib F. Unite and conquer: univariate and multivariate approaches for finding differentially expressed gene sets. Bioinformatics. 2009;25(18):2348–2354. doi:10.1093/bioinformatics/btp40619574285
   PubMed Web of Science ®Google Scholar
• Ahn T, Lee E, Huh N, Park T. Personalized identification of altered pathways in cancer using accumulated normal tissue data. Bioinformatics. 2014;30(17):i422–i429. doi:10.1093/bioinformatics/btu44925161229
   PubMed Web of Science ®Google Scholar
• Gautier L, Cope L, Bolstad BM, Irizarry RA. AFSFY – analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–315. doi:10.1093/bioinformatics/btg40514960456
   PubMed Web of Science ®Google Scholar
• Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005;33(20):e175. doi:10.1093/nar/gni17916284200
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457–D462. doi:10.1093/nar/gkv107026476454
   PubMed Web of Science ®Google Scholar
• Allan J, Leuski A, Swan R, Byrd D. Evaluating combinations of ranked lists and visualizations of inter-document similarity. Information Process Manage. 2001;37:435–458. doi:10.1016/S0306-4573(00)00056-X
   Web of Science ®Google Scholar
• Napolitano F, Sirci F, Carrella D, di Bernardo D. Drug-set enrichment analysis: a novel tool to investigate drug mode of action. Bioinformatics. 2016;32(2):235–241. doi:10.1093/bioinformatics/btv53626415724
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683. doi:10.1038/nrd146815286734
   PubMed Web of Science ®Google Scholar
• Kotelnikova E, Yuryev A, Mazo I, Daraselia N. Computational approaches for drug repositioning and combination therapy design. J Bioinform Comput Biol. 2010;8(3):593–606. doi:10.1142/S021972001000473220556864
   PubMedGoogle Scholar
• Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175–181. doi:10.1038/nature0850619881490
   PubMed Web of Science ®Google Scholar
• Zhang M, Luo H, Xi Z, Rogaeva E. Drug repositioning for diabetes based on ‘omics’ data mining. PLoS One. 2015;10(5):e0126082. doi:10.1371/journal.pone.012608225946000
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704. doi:10.1038/nrrheum.2015.11226282082
   PubMed Web of Science ®Google Scholar
• Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11(7):390–400.25825281
   PubMed Web of Science ®Google Scholar
• McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71(18):2457–2489. doi:10.2165/11208240-000000000-0000022141388
   PubMed Web of Science ®Google Scholar
• Lopez-Franco O, Hernandez-Vargas P, Ortiz-Munoz G, et al. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(8):1864–1870. doi:10.1161/01.ATV.0000229659.94020.5316741149
   PubMed Web of Science ®Google Scholar
• Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res. 2004;19(11):1905–1916. doi:10.1359/JBMR.04091915476591
   PubMed Web of Science ®Google Scholar
• Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett. 2007;254(1):119–127. doi:10.1016/j.canlet.2007.03.00217470383
   PubMed Web of Science ®Google Scholar
• Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, et al. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother. 2005;49(1):176–182. doi:10.1128/AAC.49.11.176-182.200515616293
   PubMed Web of Science ®Google Scholar
• Yonezawa T, Lee JW, Hibino A, et al. Harmine promotes osteoblast differentiation through bone morphogenetic protein signaling. Biochem Biophys Res Commun. 2011;409(2):260–265. doi:10.1016/j.bbrc.2011.05.00121570953
   PubMed Web of Science ®Google Scholar
• Hara ES, Ono M, Kubota S, et al. Novel chondrogenic and chondroprotective effects of the natural compound harmine. Biochimie. 2013;95(2):374–381. doi:10.1016/j.biochi.2012.10.01623116713
   PubMed Web of Science ®Google Scholar
• Egusa H, Doi M, Saeki M, et al. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells. Bone. 2011;49(2):264–274. doi:10.1016/j.bone.2011.04.00321504804
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Grahame R. Treatment with danazol for refractory thrombocytopenia in rheumatoid arthritis. Br J Rheumatol. 1989;28(6):550–552. doi:10.1093/rheumatology/28.6.5502590815
   PubMedGoogle Scholar
• Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Sanchez-Andrade A, Gonzalez-Gay MA. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol. 1997;36(10):1095–1099. doi:10.1093/rheumatology/36.10.10959374927
   PubMedGoogle Scholar
• Sun J, Xu P, Du X, Zhang Q, Zhu Y. Piperlongumine attenuates collagen-induced arthritis via expansion of myeloid-derived suppressor cells and inhibition of the activation of fibroblast-like synoviocytes. Mol Med Rep. 2015;11(4):2689–2694. doi:10.3892/mmr.2014.300125435301
   PubMed Web of Science ®Google Scholar
• Xiao Y, Shi M, Qiu Q, et al. Piperlongumine suppresses dendritic cell maturation by reducing production of reactive oxygen species and has therapeutic potential for rheumatoid arthritis. J Immunol. 2016;196(12):4925–4934. doi:10.4049/jimmunol.150128127183580
   PubMed Web of Science ®Google Scholar
• Xu S, Xiao Y, Zeng S, et al. Piperlongumine inhibits the proliferation, migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Inflammation Res. 2018;67(3):233–243. doi:10.1007/s00011-017-1112-9
   PubMed Web of Science ®Google Scholar
• Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017;6:Cd012095.28597983
   PubMed Web of Science ®Google Scholar
• Krasselt M, Baerwald C. Celecoxib for the treatment of musculoskeletal arthritis. Expert Opin Pharmacother. 2019;20(14):1689–1702. doi:10.1080/14656566.2019.164512331339385
   PubMed Web of Science ®Google Scholar
• Lee YS, Lee SY, Park SY, Lee SW, Hong KW, Kim CD. Cilostazol add-on therapy for celecoxib synergistically inhibits proinflammatory cytokines by activating IL-10 and SOCS3 in the synovial fibroblasts of patients with rheumatoid arthritis. Inflammopharmacology. 2019. doi:10.1007/s10787-019-00605-5
   Web of Science ®Google Scholar